{"id":1650,"date":"2026-06-17T19:46:23","date_gmt":"2026-06-17T23:46:23","guid":{"rendered":"https:\/\/www.insilens.com\/?p=1650"},"modified":"2026-07-14T21:16:41","modified_gmt":"2026-07-15T01:16:41","slug":"be-bio-terminates-be-101-hemophilia-b-program","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=1650","title":{"rendered":"Be Bio Terminates BE-101 Hemophilia B Program"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"1650\" class=\"elementor elementor-1650\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4e824ad8 e-flex e-con-boxed e-con e-parent\" data-id=\"4e824ad8\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2edee3b0 elementor-widget elementor-widget-image\" data-id=\"2edee3b0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"512\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/06\/ChatGPT-Image-Jun-17-2026-07_45_54-PM-768x512.png\" class=\"attachment-medium_large size-medium_large wp-image-1651\" alt=\"\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/06\/ChatGPT-Image-Jun-17-2026-07_45_54-PM-768x512.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/06\/ChatGPT-Image-Jun-17-2026-07_45_54-PM-300x200.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/06\/ChatGPT-Image-Jun-17-2026-07_45_54-PM-1024x683.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/06\/ChatGPT-Image-Jun-17-2026-07_45_54-PM.png 1536w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-296540d5 e-flex e-con-boxed e-con e-parent\" data-id=\"296540d5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3c9f87fc elementor-widget__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"3c9f87fc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h4>Summary<\/h4><p>Be Biopharma terminated the Phase 1\/2 BeCoMe-9 study of BE-101, the first engineered B cell medicine tested clinically in hemophilia B.<\/p><h4>What Happened<\/h4><p>The trial stopped after enrolling five patients. The company stated the decision was strategic and not driven by safety concerns.<\/p><h4>Deep Analysis<\/h4><p>This is a platform-level event. Engineered B cell medicines were positioned as a potential alternative to AAV gene therapy through durable, titratable and potentially re-dosable protein production. While not a biological failure, the termination removes the leading opportunity for clinical validation of the modality. It also reflects the increasingly difficult commercial and financing environment surrounding genetic medicines in hemophilia.<\/p><h4>Competitive Displacement<\/h4><p>Established approaches including HEMGENIX, BEQVEZ, fitusiran and concizumab face less near-term competition from engineered B cell therapies.<\/p><h4>Company \/ Product Background<\/h4><p>BE-101 was designed to engineer patient B cells to produce Factor IX without conditioning chemotherapy.<\/p><h4>Signal Extraction<\/h4><p>First B cell medicine trial terminated; no reported safety signal; platform implications beyond hemophilia; highlights capital allocation pressures in genetic medicine.<\/p><h4>Insilens Take<\/h4><p>The most important takeaway is that the field loses its best near-term proof-of-concept opportunity. This is a setback for engineered B cell therapeutics, though not evidence that the underlying science is invalid.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Be Biopharma terminated the Phase 1\/2 BeCoMe-9 study of BE-101, the first engineered B cell medicine tested clinically in hemophilia B.<\/p>\n","protected":false},"author":1,"featured_media":1651,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,3],"tags":[69,70],"class_list":["post-1650","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-therapeutic-indication","tag-be-biopharma","tag-hemophilia-b"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1650"}],"version-history":[{"count":4,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1650\/revisions"}],"predecessor-version":[{"id":1655,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1650\/revisions\/1655"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/1651"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}